Effect of an alpha 2-adrenoceptor antagonist, midaglizole, on bronchial responsiveness to histamine in patients with mild asthma.
The purpose of this study was to investigate the effects of midaglizole (MID) and interactions of MID with beta 2-agonists on bronchial hyperresponsiveness (BHR). Thirteen patients with mild asthma were randomized with respect to whether they were taking oral beta 2-agonists, and the investigators were blinded to patients' regular drug regimens. Histamine challenge test was performed before and after oral administration of MID for 1 week (300 mg/day). There was a significant increase in PC20 values in asthmatic subjects on regular therapy with beta 2-agonists (p < 0.05), whereas asthmatics not taking beta 2-agonists showed no significant change in PC20. These results suggest that MID may participate in improved BHR in the presence of beta 2-agonists and play some role in enhancing the effects of beta 2-agonists.
Sakai
H
H
First Department of Internal Medicine, Gunma University School of Medicine, Japan.
Dobashi
K
K
Nakazawa
T
T
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D016535:Bronchial Hyperreactivity / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D004347:Drug Interactions; D005260:Female; D006632:Histamine; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D007093:Imidazoles; C032368:midaglizole; D006632:Histamine